Fecal microbiota transplantation (FMT) versus placebo in patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma: Preliminary results of the randomized phase II TACITO trial

被引：1

作者：

Ciccarese, C. ^{[1
]}

Porcari, S. ^{[2
]}

Buti, S. ^{[3
]}

Fornarini, G. ^{[4
]}

Primi, F. ^{[5
]}

Giudice, G. C. ^{[6
]}

Damassi, A. ^{[7
]}

Berrios, J. R. Giron ^{[8
]}

Stumbo, L. ^{[9
]}

Arduini, D. ^{[1
]}

Severino, A. ^{[10
]}

Rondinella, D. ^{[10
]}

Masucci, L. ^{[10
]}

Sanguinetti, M. ^{[10
]}

Gasbarrini, A.

Cammarota, G. ^{[2
,11
]}

Segata, N. ^{[12
]}

Tortora, G. ^{[13
]}

Ianiro, G. ^{[10
]}

Iacovelli, R. ^{[14
]}

机构：

[1] Fdn Policlin Univ Agostino Gemelli IRCCS, Med Oncol, Rome, Italy

[2] Fdn Policlin Univ Agostino Gemelli IRCC, Dept Med & Surg Sci UOC Gastroenterol, Rome, Italy

[3] Univ Parma, Univ Hosp Parma, Dept Med & Surg, Med Oncol Unit, Parma, Italy

[4] IRCCS Osped Policlin San Martino, Dept Hematol Oncol, Genoa, Italy

[5] Osped Belcolle ASL Viterbo, Oncol, Viterbo, Italy

[6] Univ Parma, Oncol Med, Parma, Italy

[7] Asl3 Genovese, Med Oncol, Genoa, Italy

[8] Osped Belcolle ASL Viterbo, Med Oncol, Viterbo, Italy

[9] Azienda Osped Univ S Andrea, Med Oncol, Rome, Italy

[10] Fdn Policlin Univ Agostino Gemelli IRCCS, Dept Med & Surg Sci UOC Gastroen terol, Rome, Italy

[11] Univ Cattolica Sacro Cuore, Fdn Policlin Univ Agostino Gemelli IRCC, Dept Internal Med & Gastroenterol, Rome, Italy

[12] Univ Trento, Dipartimento Biol Cellulare Computaz Integrata CI, Cellular Computat & Integrat Biol CIBIO, Povo, Italy

[13] Univ Cattolica Sacro Cuore, Fdn Policlin Univ Agostino Gemelli IRCCS, Rome, Italy

[14] Fdn Policlin Univ Agostino Gemelli IRCCS, Med Oncol, Rome, Italy

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.2320

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA77

引用

页码：1264 / 1264

页数：1

共 50 条

[1] DART Study: A phase II randomized trial of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma (RCC): Results from Part 1.
Voss, Martin Henner
Plimack, Elizabeth R.
Rini, Brian I.
Atkins, Michael B.
Alter, Robert
Bhatt, Rupal Satish
Beck, J. Thaddeus
Pappas, Kristen M.
Wilson, Dawn
Zhang, Xiaosha
Sherman, Matthew L.
Pandya, Shuchi Sumant
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
[2] Fecal microbiota transplantation to improve efficacy of immune checkpoint inhibitors in renal cell carcinoma (TACITO trial).
Porcari, Serena
Ciccarese, Chiara
Pinto, Federica
Quaranta, Gianluca
De Giorgi, Silvia
Rondinella, Debora
Settanni, Carlo Romano
Cortesi, Enrico
Roberto, Michela
Primi, Francesca
Buti, Sebastiano
Fornarini, Giuseppe
Masucci, Luca
Sanguinetti, Maurizio
Gasbarrini, Antonio
Tortora, Giampaolo
Cammarota, Giovanni
Segata, Nicola
Iacovelli, Roberto
Ianiro, Gianluca
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[3] Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial
Gross-Goupil, M.
Kwon, T. G.
Eto, M.
Ye, D.
Miyake, H.
Seo, S. I.
Byun, S-S
Lee, J. L.
Master, V.
Jin, J.
DeBenedetto, R.
Linke, R.
Casey, M.
Rosbrook, B.
Lechuga, M.
Valota, O.
Grande, E.
Quinn, D. I.
ANNALS OF ONCOLOGY, 2018, 29 (12) : 2371 - 2378
[4] Results of the phase II TRAXAR study: A randomized phase II trial of axitinib and TRC105 (TRAX) versus axitinib (AX) alone in patients with advanced or metastatic renal cell carcinoma (mRCC)
Choueiri, T. K.
Kocsis, J.
Pachynski, R. K.
Poprach, A.
Deshazo, M.
Zakharia, Y.
Lara, P. N.
Pal, S. K.
Geczi, L.
Ho, T. H.
Mangel, L.
Redman, B.
Ryan, C. W.
Olencki, T.
Simpson, B. E.
Adams, B.
Robertson, L.
Darif, M.
Theuer, C.
Agarwal, N.
ANNALS OF ONCOLOGY, 2019, 30 : 362 - +
[5] Pembrolizumab plus axitinib: a new treatment option for patients with metastatic renal cell carcinoma
Mollica, Veronica
Di Nunno, Vincenzo
Massari, Francesco
CHINESE CLINICAL ONCOLOGY, 2019, 8
[6] Re: Axitinib versus Placebo as an Adjuvant Treatment of Renal Cell Carcinoma: Results from the Phase III, Randomized ATLAS Trial
Laguna, M. Pilar
JOURNAL OF UROLOGY, 2019, 202 (01): : 27 - 28
[7] Randomized Double-Blind Phase II Trial of Fecal Microbiota Transplantation Versus Placebo in Allogeneic Hematopoietic Cell Transplantation and AML
Rashidi, Armin
Ebadi, Maryam
Rehman, Tauseef Ur
Elhusseini, Heba
Kazadi, David
Halaweish, Hossam
Khan, Mohammad H.
Hoeschen, Andrea
Cao, Qing
Luo, Xianghua
Kabage, Amanda J.
Lopez, Sharon
Holtan, Shernan G.
Weisdorf, Daniel J.
Khoruts, Alexander
Staley, Christopher
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (34) : 5306 - +
[8] DART Study: A phase 2 randomized trial of dalantercept plus axitinib versus placebo plus axitinib in advanced renal cell carcinoma (RCC): Results from the part 1 dose escalation cohorts
Voss, M. H.
Plimack, E.
Rini, B.
Atkins, M. B.
Alter, R.
Beck, J. T.
Bhatt, R. S.
Pappas, K.
Wilson, D.
Sherman, M. L.
Pandya, S.
BJU INTERNATIONAL, 2014, 114 : 16 - 17
[9] A Phase IB/II Trial of Lenvatinib plus Pembrolizumab in Patients With Renal Cell Carcinoma
Lee, Chung-Han
Makker, Vicky
Rasco, Drew
Taylor, Matthew
Dutcus, Corina
Shumaker, Robert
Schmidt, Emmett
Stepan, Daniel E.
Li, Di
Young, Louise
Motzer, Robert
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 153 - 153
[10] Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
Motzer, Robert J.
Rini, Brian I.
McDermott, David F.
Redman, Bruce G.
Kuzel, Timothy M.
Harrison, Michael R.
Vaishampayan, Ulka N.
Drabkin, Harry A.
George, Saby
Logan, Theodore F.
Margolin, Kim A.
Plimack, Elizabeth R.
Lambert, Alexandre M.
Waxman, Ian M.
Hammers, Hans J.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (13) : 1430 - 1437

← 1 2 3 4 5 →